“TAKE-HOME MESSAGE
The authors assessed the impact of statin use or non-use in combination with androgen-deprivation therapy among 87,346 men with advanced prostate cancer in the national VA database. On adjusted analysis, statin use was associated with a number of favorable outcomes, including overall survival (HR, 0.66), cancer-specific survival (HR, 0.56), and a longer time before onset of skeletal-related events (HR, 0.64).”